RecruitingNot Applicable

An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma

China300 participantsStarted 2025-09-29

Plain-language summary

This study will investigate how well glofitamab-based therapy works and how safe it is in Chinese adult participants with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Histologically confirmed R/R DLBCL after one line of systemic therapy * Will be treated with Glofit-based regimen (known as being recommended and having the intention to be treated with Glofitamab at the time of signing ICF) or have initiated Glofit-based regimen treatment within three months (90 days) prior to enrollment Exclusion Criteria: * Participants who currently participate in or plan to participate in any interventional clinical trial

What they're measuring

real-world Progression-Free Survival (rwPFS)

Timeframe: Up to approximately 4 years

Trial details

NCT IDNCT07200375

SponsorHoffmann-La Roche

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2029-09-29

Contact for this trial

Reference Study ID Number: ML45172 https://forpatients.roche.com/

888-662-6728 (U.S. and Canada) global-roche-genentech-trials@gene.com

View on ClinicalTrials.gov More Diffuse Large B-Cell Lymphoma trials